RecruitingTreatment-resistant Depression (TRD)

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

Eligible age

18–75 yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.

Sponsor: Alto Neuroscience

✓ Male and female participants, ages 18 to 75 years, inclusive, at the time of signing the ICF.
✓ Prior diagnosis of MDD without psychotic symptoms (in the current episode) and have confirmatory diagnosis of current MDD (moderate to severe).
✓ Failure to respond (\<50% improvement) to at least 2-5 antidepressant treatments (including the current treatment)
✓ Currently taking a stable dose of at least 1 but no more than 2 oral antidepressants at baseline

✕ Evidence of unstable medical condition
✕ Concurrent use of any prohibited medications or substance use disorder
✕ Diagnosed bipolar disorder or a psychotic disorder or symptoms
✕ Significant current PTSD symptoms or history of PTSD
✕ Clinically significant current impulse control difficulties
✕ Has a history of hypersensitivity or allergic reaction to ALTO-207 or any of its components/excipients
✕ Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device